Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,147
- Phase 21,063
- Phase 1819
- Phase 1/Phase 2442
- Phase 3425
- Phase 4238
- Phase 2/Phase 396
Top conditions
- Multiple Sclerosis343
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis140
- Type 1 Diabetes133
- Atopic Dermatitis129
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Type 1 Diabetes Mellitus63
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)73
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals60
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California491
- Maryland195
- Alabama175
- Florida144
- Arizona142
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT07106710RecruitingPhase 2
Stem cell transplant plus two targeted therapies for ultra-high-risk myeloma
This trial tests a stem cell transplant followed by two targeted therapies — a BCMA CAR-T and a GPRC5D/CD3 bispecific antibody — to treat newly diagnosed multiple myeloma that has ultra-high-risk features. The goal is to see if this combination can better control the disease.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07106736RecruitingPhase 2
CAR-T for newly diagnosed multiple myeloma without transplant
This trial is testing a new immunotherapy treatment using CAR-T cells for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The treatment aims to target and destroy myeloma cells that have BCMA and GPRC5D proteins on their surface.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07106749RecruitingPhase 1
CD180 car T cells for blood cancers that came back
This trial tests a new CAR T cell therapy that targets a protein called CD180 on cancer cells. It is for people with certain types of relapsed or refractory leukemia or lymphoma that has not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07107529RecruitingPhase 2
Study of daratumumab with teclistamab or talquetamab for frail patients with newly diagnosed multiple myeloma
This trial tests a combination of drugs—daratumumab plus either teclistamab or talquetamab—for people who have just been diagnosed with multiple myeloma and are considered frail. The goal is to see if this treatment is safe and effective for those who may not be strong enough for standard therapies.
Ascoli PicenoAges 18 years+ - NCT07107659RecruitingEarly Phase 1
Testing ONT01 for active lupus
This trial tests a new drug called ONT01 for people with active lupus that is not affecting their kidneys. It is for those who have not had success with standard treatments.
New York, New YorkAges 18 years+ - NCT07108868RecruitingPhase 1
Study of MB-CART2219.1 for blood cancers
This trial tests a new CAR T-cell therapy called MB-CART2219.1 in people with certain types of blood cancer (like lymphoma or leukemia) that have come back or not responded to other treatments. CAR T-cells are your own immune cells that are modified to better find and kill cancer cells.
Tübingen, Baden-WurttembergAges 12–75 - NCT07108998RecruitingPhase 2
Epcoritamab as a follow-up treatment for CLL or SLL
This trial tests the drug epcoritamab as a consolidation therapy for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have had a partial response to a second-generation BTK inhibitor (with or without obinutuzumab) but still have detectable disease. The goal is to see if adding this treatment can lead to a deeper response and better outcomes.
Cincinnati, OhioAges 18 years+ - NCT07109219RecruitingPhase 1/Phase 2
Study of AZD4512 for adults and teens with relapsed B-ALL
This trial tests a new drug called AZD4512, alone or with other cancer drugs, for people whose B-ALL has come back or did not respond to treatment. It may be an option if you have tried at least 2 prior therapies or have no standard options left.
Duarte, CaliforniaAges 12 years+ - NCT07109323RecruitingPhase 1/Phase 2
Stem cell transplant plus CAR-T for aggressive myeloma
This trial tests combining a stem cell transplant with a special immune cell therapy (BCMA CAR-T) to treat very aggressive multiple myeloma. The goal is to see if this powerful one-two punch can help people whose myeloma is hard to control.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07109518RecruitingPhase 1
CD7 CAR T-Cell Therapy for Blood Cancers That Return or Don't Respond
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07109986RecruitingPhase 1
Study of UB-VV410 for active lupus or lupus nephritis
This trial tests a new treatment, UB-VV410, for people with active systemic lupus erythematosus (SLE) or lupus nephritis (kidney inflammation caused by lupus) that hasn't responded to standard treatments. It aims to see if this therapy can help control the disease.
NanjingAges 18–65 - NCT07110116Recruiting
Breathing exercises with a spirometer for asthma patients
This trial tests whether combining alternate nostril breathing with an incentive spirometer improves lung function in people with asthma. It may help you breathe better if your asthma is mild to moderate and stable.
Abbottābād, Khyber PkahtoonKhwaAges 18–60 - NCT07110311Recruiting
How pet cats affect nose and gut bacteria in cat allergy patients
This study looks at how living with a pet cat might affect the bacteria in your nose and gut if you have dust mite and cat allergies. It could help us understand if cats actually change your allergy symptoms or the balance of bugs in your body.
Nanjing, JiangsuAges 18–65 - NCT07111598Recruiting
Iron supplements and the immune system in HHT
This study looks at how iron supplements affect the immune system in people with HHT (a genetic condition that causes bleeding from abnormal blood vessels). You may be placed in one of three groups depending on your iron and ferritin levels.
Bron, RhoneAges 18–99 - NCT07111884Recruiting
Multiple myeloma registry study
This study collects information from multiple myeloma patients who previously took part in a GMMG therapy study. It helps researchers learn more about the disease and treatments over time.
BerlinAges 18 years+ - NCT07113262RecruitingPhase 3
Study of IBI311 for people with inactive thyroid eye disease
This trial tests a new medication called IBI311 for people whose thyroid eye disease is no longer active but still causes bulging eyes. It aims to see if the drug can reduce eye bulging safely.
Shenyang, LiaoningAges 18–80 - NCT07113626Recruiting
HIV testing and PrEP study for young men in Hanoi
This study tests a program to help young men who have sex with men in Hanoi get HIV testing and PrEP (medication to prevent HIV). The goal is to see if a phone-based tool can make it easier to access these services.
HanoiAges 18 years+ - NCT07114367RecruitingPhase 1
NB02 for relapsed non-Hodgkin's lymphoma
This trial tests a new oral drug (NB02) for people with certain types of non-Hodgkin's lymphoma that have come back or not responded to at least two prior treatments. It aims to see if the drug can shrink tumors and control the disease.
HwasunAges 19–80 - NCT07114809Recruiting
Can brain stimulation and virtual reality boost thinking in MS?
This study tests whether a combination of gentle brain stimulation (tDCS) and virtual reality exercises can improve memory and thinking problems in people with multiple sclerosis. If you have mild to moderate disability and no major health issues, you may be able to join.
Genova, ItalyAges 18–65 - NCT07114939RecruitingPhase 1
A new pet scan for pancreatic neuroendocrine tumors
This study is testing a special type of PET/CT scan using a tracer called FTT to see if it can better find and track pancreatic neuroendocrine tumors that have spread or cannot be removed by surgery. The goal is to improve imaging for people with this type of cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07115017Recruiting
Testing a new PET scan tracer for brain inflammation in MS
This study uses a new radioactive tracer called [18F]-FZTA during a PET scan to see inflammation in the brain. Researchers want to test this tracer in both healthy adults and people with multiple sclerosis (MS) to see if it can help detect MS activity.
St Louis, MissouriAges 18 years+ - NCT07115342Recruiting
Probiotics and vitamin D for hay fever relief
This study tests whether taking a combination of probiotics (good bacteria) and vitamin D can help reduce hay fever symptoms. It may be a good option if your vitamin D is low and you haven't used probiotics recently.
Tanta, Gharbia GovernorateAges 18–65 - NCT07115745RecruitingPhase 1
Donor CAR T cells for severe autoimmune diseases
This study tests a new type of CAR T-cell therapy made from healthy donor cells. It is designed to help people with severe autoimmune diseases that have not improved with standard treatments.
Boston, MassachusettsAges 18 years+ - NCT07116031RecruitingPhase 2
Belumosudil for children with chronic GVHD
This study tests a new medicine called belumosudil for children with chronic graft-versus-host disease (GVHD) that hasn't improved with at least 2 other treatments. The goal is to see if it can help control the disease and improve symptoms.
Los Angeles, CaliforniaAges 1–18
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,763 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.